Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuncts to levodopa therapy: dopamine agonists

W Poewe1

  • 1Department of Neurology, University Hospital Innsbruck, Austria.

Neurology
|June 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional connectivity and topology in patients with restless legs syndrome: a case-control resting-state functional magnetic resonance imaging study.

European journal of neurology·2020
Same author

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

European journal of neurology·2019
Same author

Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.

European journal of neurology·2018
Same author

Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport<sup>®</sup> ).

European journal of neurology·2018
Same author

The neuropsychiatric phenotype in CACNA1A mutations: a retrospective single center study and review of the literature.

European journal of neurology·2018
Same author

Response to: On the role of visual electrophysiology in parkinson's disease.

Parkinsonism & related disorders·2017
Same journal

Teaching Video NeuroImage: Tardive Blepharoclonus.

Neurology·2026
Same journal

Teaching NeuroImage: Latent Axonal Degeneration in Patient With Anterior Circulation Stroke.

Neurology·2026
Same journal

Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

Neurology·2026
Same journal

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same journal

Digital Semiology.

Neurology·2026
Same journal

Early Cerebral Edema Subtypes and Functional Outcome in Patients With Cerebral Venous Thrombosis: Insights From the CLOT-VENUS Registry.

Neurology·2026
See all related articles

Dopamine agonists are used with levodopa for Parkinson's disease (PD) to manage motor fluctuations. Research explores their use as initial monotherapy and in continuous infusions, but an ideal agonist remains elusive.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Dopamine agonists are traditionally used as add-on therapy in Parkinson's disease (PD) to manage motor fluctuations associated with levodopa treatment.
  • These fluctuations include "wearing-off" periods and more severe "on-off" swings, impacting patient quality of life.

Purpose of the Study:

  • To review the clinical pharmacology of dopamine agonists in Parkinson's disease.
  • To explore the evolving role of dopamine agonists, including their use in early monotherapy and continuous delivery systems.

Main Methods:

  • Review of existing literature on dopamine agonist therapy in Parkinson's disease.
  • Analysis of studies investigating monotherapy, combination therapy, and novel delivery methods.

Main Results:

Related Experiment Videos

  • Dopamine agonists effectively reduce "off" time and allow for levodopa dose reduction.
  • Early monotherapy shows low rates of dyskinesia but limited long-term success (approx. 30% beyond 3 years).
  • Continuous dopaminergic stimulation and early combined therapy are under investigation but remain controversial.

Conclusions:

  • The ideal dopamine agonist with long-acting properties and levodopa-equivalent efficacy is still needed.
  • Further research is required to optimize dopamine agonist therapy for Parkinson's disease management.